Tags

Type your tag names separated by a space and hit enter

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1998 May; 64(5):573-6.JN

Abstract

OBJECTIVES

To determine whether continuous waking day dopaminergic stimulation with the dopamine agonist apomorphine can reduce levodopa induced dyskinesias in Parkinson's disease

METHODS

19 patients with severe unpredictable refractory motor fluctuations and functionally disabling levodopa induced dyskinesias were treated with continuous subcutaneous apomorphine monotherapy for a minimum duration of 2.7 years

RESULTS

A mean 65% reduction in dyskinetic severity and a mean 85% reduction in frequency and duration occurred. On discontinuing levodopa a concomitant reduction in off period time was also seen (35% of waking day "off" reduced to 10%)

CONCLUSION

Continuous waking day dopaminergic stimulation with apomorphine reset the threshold for dyskinesias and led to a pronounced reduction in their frequency. Apomorphine should be considered as a less invasive alternative to pallidotomy or deep cerebral stimulation in controlling levodopa induced interdose dose dyskinesias.

Authors+Show Affiliations

Department of Neurological Sciences, Middlesex Hospital, London, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9598668

Citation

Colzi, A, et al. "Continuous Subcutaneous Waking Day Apomorphine in the Long Term Treatment of Levodopa Induced Interdose Dyskinesias in Parkinson's Disease." Journal of Neurology, Neurosurgery, and Psychiatry, vol. 64, no. 5, 1998, pp. 573-6.
Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(5):573-6.
Colzi, A., Turner, K., & Lees, A. J. (1998). Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 64(5), 573-6.
Colzi A, Turner K, Lees AJ. Continuous Subcutaneous Waking Day Apomorphine in the Long Term Treatment of Levodopa Induced Interdose Dyskinesias in Parkinson's Disease. J Neurol Neurosurg Psychiatry. 1998;64(5):573-6. PubMed PMID: 9598668.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. AU - Colzi,A, AU - Turner,K, AU - Lees,A J, PY - 1998/5/23/pubmed PY - 1998/5/23/medline PY - 1998/5/23/entrez SP - 573 EP - 6 JF - Journal of neurology, neurosurgery, and psychiatry JO - J Neurol Neurosurg Psychiatry VL - 64 IS - 5 N2 - OBJECTIVES: To determine whether continuous waking day dopaminergic stimulation with the dopamine agonist apomorphine can reduce levodopa induced dyskinesias in Parkinson's disease METHODS: 19 patients with severe unpredictable refractory motor fluctuations and functionally disabling levodopa induced dyskinesias were treated with continuous subcutaneous apomorphine monotherapy for a minimum duration of 2.7 years RESULTS: A mean 65% reduction in dyskinetic severity and a mean 85% reduction in frequency and duration occurred. On discontinuing levodopa a concomitant reduction in off period time was also seen (35% of waking day "off" reduced to 10%) CONCLUSION: Continuous waking day dopaminergic stimulation with apomorphine reset the threshold for dyskinesias and led to a pronounced reduction in their frequency. Apomorphine should be considered as a less invasive alternative to pallidotomy or deep cerebral stimulation in controlling levodopa induced interdose dose dyskinesias. SN - 0022-3050 UR - https://www.unboundmedicine.com/medline/citation/9598668/Continuous_subcutaneous_waking_day_apomorphine_in_the_long_term_treatment_of_levodopa_induced_interdose_dyskinesias_in_Parkinson's_disease_ L2 - https://jnnp.bmj.com/lookup/pmidlookup?view=long&pmid=9598668 DB - PRIME DP - Unbound Medicine ER -